Used in the treatment of hemophilia A and B, particularly in patients with inhibitors to factor VIII or IX. It functions by inhibiting tissue factor pathway inhibitor (TFPI), thereby promoting thrombin generation and restoring hemostasis. Administered subcutaneously, it offers a prophylactic option to reduce bleeding episodes with a once-daily or less frequent dosing regimen. Its mechanism supports bypassing the need for replacement clotting factors, making it a valuable option in inhibitor management.